AI Insight
The article examines the scientific evidence behind popular anti-aging supplements, specifically those containing NMN (nicotinamide mononucleotide), NAD+ (nicotinamide adenine dinucleotide), and resveratrol, which are marketed as compounds capable of slowing cellular aging processes. These supplements target biological pathways involved in cellular energy metabolism and DNA repair, particularly the decline in NAD+ levels that occurs with age. While some preclinical studies in animal models show promising results, human clinical trial evidence remains limited, mixed, and insufficient to support strong conclusions about their efficacy.
Why it matters
The anti-aging supplement market represents a multi-billion dollar industry, and consumers deserve accurate, evidence-based information before investing in products that may offer limited demonstrated benefit. Clarifying the gap between animal study results and human clinical outcomes is essential for guiding both public health decisions and future research priorities.
As more people look for ways to stay younger for longer, the supplement industry has moved beyond creams and cosmetic fixes to something more ambitious: products that claim to slow aging by acting on cellular processes.